SCHEMBL2665022

SCHEMBL2665022

Cc1cccc(S(=O)(=O)Nc2ccccc2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.73
MEN1 O00255 4/20 0.73
ALDH1A1 P00352 4/20 0.68
MAPT P10636 2/20 0.68
HPGD P15428 1/20 0.68
CA12 O43570 1/20 0.66
CA1 P00915 1/20 0.66
CA2 P00918 1/20 0.66
CA9 Q16790 1/20 0.66
IL1RN P18510 1/20 0.66
KEAP1 Q14145 1/20 0.66
ERAP1 Q9NZ08 1/20 0.66
PGR P06401 2/20 0.65
POLB P06746 1/20 0.65
PKM P14618 1/20 0.61
GAA P10253 1/20 0.58
HDAC8 Q9BY41 2/20 0.58
HDAC1 Q13547 1/20 0.58
PTPN2 P17706 1/20 0.56
PTPN1 P18031 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15045213 0.91 KMT2A (0.71) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL31681311 0.89 CA12 (0.66) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL21693592 0.89 KMT2A (0.73) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL259382 0.89 CA12 (0.66) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL17102994 0.88 MAPT (0.67) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL8081768 0.87 KEAP1 (0.79) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL15045212 0.86 KMT2A (0.69) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL15045215 0.85 KMT2A (0.68) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL22455328 0.85 PGR (0.72) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL95092 0.85 KMT2A (0.68) KMT2AMEN1ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024008833-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY ZOUNEK ALEX (DE) 2024-01-11 WO disclosed
WO-2022081984-A1 METHODS AND COMPOUNDS TO TREAT SARS INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-04-21 WO disclosed
US-8936840-B2 Retardation film, polarizing plate, liquid crystal display device, and compound Konica Minolta, Inc. (JP) 2015-01-20 US disclosed
US-8936840-B2 Retardation film, polarizing plate, liquid crystal display device, and compound Konica Minolta, Inc. (JP) 2015-01-20 US disclosed
EP-2203421-B1 METHODS OF SYNTHESIS OF CERTAIN N-HYDROXY-3-(3-PHENYLSULFAMOYL-PHENYL)-ACRYLAMIDE COMPOUNDS TOPOTARGET UK LTD (GB) 2014-05-07 EP disclosed
US-20130040998-A1 FLUORINATED HDAC INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2013-02-14 US disclosed
EP-1377642-B1 COLORING COMPOSITION FOR IMAGE FORMATION AND METHOD FOR IMPROVING OZONE RESISTANCE OF COLOR IMAGE FUJIFILM CORP (JP) 2013-01-09 EP disclosed
WO-2007006546-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS DEVGEN N.V. (BE) 2007-01-18 WO disclosed
WO-2003048109-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2003-06-12 WO disclosed
WO-2002040445-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-05-23 WO disclosed
US-4053458-A INHIBITORS UOP INC. (US) 1977-10-11 US disclosed
US-4022828-A BIS-(SULFONAMIDO)-SULFIDES UNIVERSAL OIL PRODUCTS COMPANY (US) 1977-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040998-A1 FLUORINATED HDAC INHIBITORS AND USES THEREOF HDAC1, HDAC5, HDAC6 KMT2A 72/4885MEN1 3462/4885ALDH1A1 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.